These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17898154)

  • 21. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
    Kaji H; Kume T
    Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant.
    Fang JL; Lazarus P
    Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):102-9. PubMed ID: 14744740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes.
    Yamanaka H; Nakajima M; Katoh M; Yokoi T
    Drug Metab Dispos; 2007 Sep; 35(9):1642-8. PubMed ID: 17591679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
    Cai H; Nguyen N; Peterkin V; Yang YS; Hotz K; La Placa DB; Chen S; Tukey RH; Stevens JC
    Drug Metab Dispos; 2010 May; 38(5):879-86. PubMed ID: 20124398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
    Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
    Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver.
    Girard H; Thibaudeau J; Court MH; Fortier LC; Villeneuve L; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Hepatology; 2005 Aug; 42(2):448-57. PubMed ID: 15986396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
    Hanioka N; Naito T; Narimatsu S
    Chemosphere; 2008 Dec; 74(1):33-6. PubMed ID: 18990428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.
    Rowbotham SE; Illingworth NA; Daly AK; Veal GJ; Boddy AV
    Drug Metab Dispos; 2010 Jul; 38(7):1211-7. PubMed ID: 20308471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.
    Miners JO; Bowalgaha K; Elliot DJ; Baranczewski P; Knights KM
    Drug Metab Dispos; 2011 Apr; 39(4):644-52. PubMed ID: 21245288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
    Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC
    Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver.
    Mano Y; Usui T; Kamimura H
    Drug Metab Dispos; 2007 Nov; 35(11):2040-4. PubMed ID: 17670842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans.
    Kato Y; Ikushiro S; Emi Y; Tamaki S; Suzuki H; Sakaki T; Yamada S; Degawa M
    Drug Metab Dispos; 2008 Jan; 36(1):51-5. PubMed ID: 17908920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the Differences of UGT1A1 Activity in Recombinant UGT1A1 Enzyme, Human Liver Microsomes and Rat Liver Microsome Incubation Systems in Vitro.
    Wang Q; Dai Z; Wen B; Ma S; Zhang Y
    Biol Pharm Bull; 2015; 38(12):1910-7. PubMed ID: 26632182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
    Innocenti F; Grimsley C; Das S; Ramírez J; Cheng C; Kuttab-Boulos H; Ratain MJ; Di Rienzo A
    Pharmacogenetics; 2002 Dec; 12(9):725-33. PubMed ID: 12464801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.
    Borlak J; Gasparic A; Locher M; Schupke H; Hermann R
    Metabolism; 2006 Jun; 55(6):711-21. PubMed ID: 16713428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
    Zhou J; Tracy TS; Remmel RP
    Drug Metab Dispos; 2011 Feb; 39(2):322-9. PubMed ID: 21030469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.